Now showing items 1-4 of 4

    • Adverse Health Outcomes in Relationship to Hypogonadism After Chemotherapy: A Multicenter Study of Testicular Cancer Survivors. 

      Abu Zaid, M; Dinh, PC; Monahan, PO; Fung, C; El-Charif, O; Feldman, DR; Hamilton, RJ; Vaughn, DJ; Beard, CJ; Cook, R; Althouse, S; Ardeshir-Rouhani-Fard, S; Sesso, HD; Huddart, R; Mushiroda, T; Kubo, M; Dolan, ME; Einhorn, LH; Fossa, SD; Travis, LB; Platinum Study Group (2019-05)
      Background This study examined the prevalence of hypogonadism, its clinical and genetic risk factors, and its relationship to adverse health outcomes (AHOs) in North American testicular cancer survivors (TCS) after modern ...
    • Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study. 

      Kerns, SL; Fung, C; Monahan, PO; Ardeshir-Rouhani-Fard, S; Abu Zaid, MI; Williams, AM; Stump, TE; Sesso, HD; Feldman, DR; Hamilton, RJ; Vaughn, DJ; Beard, C; Huddart, RA; Kim, J; Kollmannsberger, C; Sahasrabudhe, DM; Cook, R; Fossa, SD; Einhorn, LH; Travis, LB; Platinum Study Group (2018-05)
      Purpose In this multicenter study, we evaluated the cumulative burden of morbidity (CBM) among > 1,200 testicular cancer survivors and applied factor analysis to determine the co-occurrence of adverse health outcomes (AHOs). ...
    • ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. 

      Honecker, F; Aparicio, J; Berney, D; Beyer, J; Bokemeyer, C; Cathomas, R; Clarke, N; Cohn-Cedermark, G; Daugaard, G; Dieckmann, K-P; Fizazi, K; Fosså, S; Germa-Lluch, JR; Giannatempo, P; Gietema, JA; Gillessen, S; Haugnes, HS; Heidenreich, A; Hemminki, K; Huddart, R; Jewett, MAS; Joly, F; Lauritsen, J; Lorch, A; Necchi, A; Nicolai, N; Oing, C; Oldenburg, J; Ondruš, D; Papachristofilou, A; Powles, T; Sohaib, A; Ståhl, O; Tandstad, T; Toner, G; Horwich, A (2018-08)
      The European Society for Medical Oncology (ESMO) consensus conference on testicular cancer was held on 3-5 November 2016 in Paris, France. The conference included a multidisciplinary panel of 36 leading experts in the ...
    • Testosterone replacement in young male cancer survivors: A 6-month double-blind randomised placebo-controlled trial. 

      Walsh, JS; Marshall, H; Smith, IL; Greenfield, DM; Swain, J; Best, E; Ashton, J; Brown, JM; Huddart, R; Coleman, RE; Snowden, JA; Ross, RJ (2019-11-12)
      BACKGROUND:Young male cancer survivors have lower testosterone levels, higher fat mass, and worse quality of life (QoL) than age-matched healthy controls. Low testosterone in cancer survivors can be due to orchidectomy or ...